In chronic myelogenous leukemia (CML), certain white blood cells undergo a gain-of-function mutation resulting in a totally new protein.This cancer-inducing protein has unregulated enzymatic activity that promotes cell division.Based on this information, which treatment option would be the best fit for CML?

Question

Quizplus · Accepted Answer

Using molecular medicine to produce a drug to inhibit the protein's activity would be the best fit for CML since the cancer-inducing protein has unregulated enzymatic activity that promotes cell division. It would be necessary to find a way to inhibit the protein's activity to slow down the division of the affected white blood cells. Option A, supplying the correct protein intravenously, would not address the overactive protein causing the issue. Option C, using gene therapy to insert a new gene to supply the correct protein, may not be a feasible option since the mutated protein is already present and would continue promoting cell division. Option D, putting the patient on a restrictive diet, would not directly target the cancer cells or the mutated protein causing the issue, and Option E is incorrect since there are drug treatments available to inhibit enzymatic activity.

In Chronic Myelogenous Leukemia (CML), Certain White Blood Cells Undergo